49c, page-9

In Post: 2483086/ et_obrien did sayeth
"Hmmm, well there are 400 million of so shares issued, and Avexa has about $70 million in cash, so that's about $0.18 per share.

Huntley's reckons they will need the 70mil and then some to fund the phase 3 study."
(Posted: 22/01/08 17:45)

AVX closes at -0.365. Most notable thing about this stock is that will succeed or fail on the quality of ATC as a beneficial medicine, in other words the economy has little to do with it.

I'm holding on to this one - I think it represents my best chance at a substantial gain in the next 12 months.

I'm not bothered by the costs that Phase-3 may incur. If the final report on phase-2 is as good as the prelininary results suggest, AVX will have no trouble in even the most stressed out times of another capital raising.

I maintain a sentiment of 'hold', with the proviso that those feeling adventurous may buy. In times like this I could hardly recommend anybody buy anything unless they were feeling adventurous.

If the A.S.X. rebounds, then buy. In any normal trading environment I would advocate AVX at any price below 0.60,
however in times like this you may sit around and see if you can get it for 0.33.